These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 31869751)

  • 1. Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy.
    Perri F; Ionna F; Longo F; Della Vittoria Scarpati G; De Angelis C; Ottaiano A; Botti G; Caponigro F
    Transl Oncol; 2020 Feb; 13(2):262-274. PubMed ID: 31869751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
    Szturz P; Vermorken JB
    BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
    Saada-Bouzid E; Peyrade F; Guigay J
    Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The Immune Checkpoints Inhibitors for Head and Neck Cancer].
    Yokota T
    Gan To Kagaku Ryoho; 2019 Jan; 46(1):21-27. PubMed ID: 30765636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.
    Van den Bossche V; Zaryouh H; Vara-Messler M; Vignau J; Machiels JP; Wouters A; Schmitz S; Corbet C
    Drug Resist Updat; 2022 Jan; 60():100806. PubMed ID: 35121337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.
    Harrington KJ; Ferris RL; Gillison M; Tahara M; Argiris A; Fayette J; Schenker M; Bratland Å; Walker JWT; Grell P; Even C; Chung CH; Redman R; Coutte A; Salas S; Grant C; de Azevedo S; Soulières D; Hansen AR; Wei L; Khan TA; Miller-Moslin K; Roberts M; Haddad R
    JAMA Oncol; 2023 Jun; 9(6):779-789. PubMed ID: 37022706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Patel B; Saba NF
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translational Research: A Future Strategy for Managing Squamous Cell Carcinoma of the Head and Neck?
    Caponigro F; Ionna F; Scarpati GDV; Longo F; Addeo R; Manzo R; Muto P; Pisconti S; Leopaldi L; Perri F
    Anticancer Agents Med Chem; 2018; 18(9):1220-1227. PubMed ID: 29637868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Squamous cell carcinoma of head and neck: what internists should know.
    Jung K; Narwal M; Min SY; Keam B; Kang H
    Korean J Intern Med; 2020 Sep; 35(5):1031-1044. PubMed ID: 32663913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for head and neck cancer: Fundamentals and therapeutic development.
    Okano S
    Auris Nasus Larynx; 2024 May; 51(4):684-695. PubMed ID: 38729034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour-agnostic plasma assay for circulating tumour DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor.
    Honoré N; van der Elst A; Dietz A; van Marcke C; Helaers R; Mendola A; Dahou H; Marbaix E; Poncin R; Seront E; Schmitz S; Limaye N; Galot R; Machiels JP
    Eur J Cancer; 2023 Dec; 195():113372. PubMed ID: 37913682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer.
    Wagner SM; Magnes T; Melchardt T; Kiem D; Weiss L; Neureiter D; Wagner C; Aretin MB; Nemec S; Gamerith G; Pall G; Greil R; Fuereder T
    Anticancer Res; 2023 Mar; 43(3):1273-1282. PubMed ID: 36854497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
    Poulose JV; Kainickal CT
    World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant immunotherapy in head and neck cancer: Rationale, current evidence and future perspective.
    Cabezas-Camarero S; Pérez-Segura P
    Crit Rev Oncol Hematol; 2022 Jan; 169():103569. PubMed ID: 34890800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in head and neck cancer: Harnessing profit on a system disruption.
    Rancoule C; Vallard A; Espenel S; Guy JB; Xia Y; El Meddeb Hamrouni A; Rodriguez-Lafrasse C; Chargari C; Deutsch E; Magné N
    Oral Oncol; 2016 Nov; 62():153-162. PubMed ID: 27623508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.
    Botticelli A; Cirillo A; Strigari L; Valentini F; Cerbelli B; Scagnoli S; Cerbelli E; Zizzari IG; Rocca CD; D'Amati G; Polimeni A; Nuti M; Merlano MC; Mezi S; Marchetti P
    Front Immunol; 2021; 12():705096. PubMed ID: 34434192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune profiles in primary squamous cell carcinoma of the head and neck.
    Saloura V; Izumchenko E; Zuo Z; Bao R; Korzinkin M; Ozerov I; Zhavoronkov A; Sidransky D; Bedi A; Hoque MO; Koeppen H; Keck MK; Khattri A; London N; Kotlov N; Fatima A; Vougiouklakis T; Nakamura Y; Lingen M; Agrawal N; Savage PA; Kron S; Kline J; Kowanetz M; Seiwert TY
    Oral Oncol; 2019 Sep; 96():77-88. PubMed ID: 31422218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boosting the Immune Response with the Combination of Electrochemotherapy and Immunotherapy: A New Weapon for Squamous Cell Carcinoma of the Head and Neck?
    Longo F; Perri F; Caponigro F; Della Vittoria Scarpati G; Guida A; Pavone E; Aversa C; Muto P; Giuliano M; Ionna F; Solla R
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32998297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?
    von der Grün J; Rödel F; Brandts C; Fokas E; Guckenberger M; Rödel C; Balermpas P
    Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30987257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer.
    Kadono T; Yamamoto S; Kato K
    Jpn J Clin Oncol; 2022 Oct; 52(10):1089-1096. PubMed ID: 36047845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.